Compare DNN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | FTRE |
|---|---|---|
| Founded | 1954 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 1998 | 2023 |
| Metric | DNN | FTRE |
|---|---|---|
| Price | $2.21 | $21.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | $4.73 | ★ $22.63 |
| AVG Volume (30 Days) | ★ 26.8M | 1.9M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $321.58 | N/A |
| Revenue Next Year | $38.26 | $3.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $2.10 | $8.55 |
| 52 Week High | $4.43 | $26.16 |
| Indicator | DNN | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 45.85 |
| Support Level | $2.10 | $16.34 |
| Resistance Level | $3.43 | $21.25 |
| Average True Range (ATR) | 0.12 | 1.36 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 23.44 | 15.57 |
Denison Mines Corp is engaged in uranium mining-related activities, including the acquisition, exploration, development, and mining of uranium-bearing properties, as well as the processing, sale, and investment in uranium. The company's key properties include Wheeler River, Waterbury Lake, McClean Lake, Midwest, and others. It operates through two segments: the Mining segment and the Corporate and Other segment. The majority of the company's revenue is generated from the Mining segment, which includes activities related to exploration, evaluation, and development, mining, milling (including toll milling), and the sale of mineral concentrates.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.